Table 1.

Characteristics of sorafenib, lenvatinib, and cabozantinib.

Drug	Target	Half-Life in Plasma	Metabolism	Approval for DTC	Structure
Sorafenib	VEGFR-2 and -3 PDGFR, c-Kit, RET/PTC, RAF [41]	36 h [41]	Hepatic CYP3A4 and UGT1A9 [42]	2013 [43]
Lenvatinib	$\mathrm{VEGFR} 1-3, \mathrm{PDGFR}-\alpha$, RET, c-KIT, FGFR 1-4 [3]	28 h [44]	Hepatic CYP3A4 [45]	2015 [28]
Cabozantinib	VEGFR-2, c-MET, RET [31]	100–120 h [46]	Hepatic CYP3A4 [46]	2021 [47]

Structures were drawn with ChemDraw Professional 17 (Perkin Elmer Informatics, Waltham, MA, USA).